Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (191-200 of 502) with videos related to

Pageof 51
Sort By:
The Oncologist|January 11, 2024
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung CancerDavid E Gerber, Yating Wang, Suresh S Ramalingam, et al.
American Journal of Cancer Research|November 9, 2020
The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated METDanlei Yu, Yiting Li, Keven Dy Sun, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 19, 1996
A defect in glycosylphosphatidylinositol (GPI) transamidase activity in mutant K cells is responsible for their inability to display GPI surface proteinsR Chen, S Udenfriend, G M Prince, et al.
Cancer Letters|July 12, 2012
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivoHui Ren, Mingwei Chen, Ping Yue, et al.
Nature Cell Biology|January 9, 2001
Binding to the transferrin receptor is required for endocytosis of HFE and regulation of iron homeostasisT S Ramalingam, A P West, J A Lebrón, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2013
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trialsSuzanne E Dahlberg, Joan H Schiller, Philip B Bonomi, et al.
The Journal of Experimental Medicine|September 19, 2024
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancerZhen Chen, Karin A Vallega, Dongsheng Wang, et al.
The Journal of Clinical Investigation|March 7, 2024
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer modelsZhen Chen, Karin A Vallega, Dongsheng Wang, et al.
Clinical Lung Cancer|February 9, 2021
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in ProgressShun Lu, Ignacio Casarini, Terufumi Kato, et al.
Clinical Lung Cancer|May 20, 2017
Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung CancerApar Kishor Ganti, Fred R Hirsch, Murry W Wynes, et al.
Pageof 51

Showing results (191-200 of 502) with videos related to

Sort By:
Pageof 51
The Oncologist|January 11, 2024
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung CancerDavid E Gerber, Yating Wang, Suresh S Ramalingam, et al.
American Journal of Cancer Research|November 9, 2020
The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated METDanlei Yu, Yiting Li, Keven Dy Sun, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 19, 1996
A defect in glycosylphosphatidylinositol (GPI) transamidase activity in mutant K cells is responsible for their inability to display GPI surface proteinsR Chen, S Udenfriend, G M Prince, et al.
Cancer Letters|July 12, 2012
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivoHui Ren, Mingwei Chen, Ping Yue, et al.
Nature Cell Biology|January 9, 2001
Binding to the transferrin receptor is required for endocytosis of HFE and regulation of iron homeostasisT S Ramalingam, A P West, J A Lebrón, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2013
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trialsSuzanne E Dahlberg, Joan H Schiller, Philip B Bonomi, et al.
The Journal of Experimental Medicine|September 19, 2024
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancerZhen Chen, Karin A Vallega, Dongsheng Wang, et al.
The Journal of Clinical Investigation|March 7, 2024
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer modelsZhen Chen, Karin A Vallega, Dongsheng Wang, et al.
Clinical Lung Cancer|February 9, 2021
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in ProgressShun Lu, Ignacio Casarini, Terufumi Kato, et al.
Clinical Lung Cancer|May 20, 2017
Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung CancerApar Kishor Ganti, Fred R Hirsch, Murry W Wynes, et al.
Pageof 51